SK Biopharmaceuticals Q3 Operating Profit Rises 65.9% Year-on-Year
Bitget2026/11/05 00:55- SK Biopharmaceuticals’ third-quarter 2026 operating profit rose 65.9% year over year to KRW 116.28 billion.
- Revenue increased 34.8% from a year earlier to KRW 258.42 billion.
- Net profit fell 23.9% year over year to KRW 54.34 billion.
- For the first nine months of 2026, operating profit climbed 92.3% to KRW 303.12 billion.
- Nine-month revenue grew 43.2% to KRW 733.67 billion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Production Increase Falls Short, Layoffs First! Boeing (BA.US) Cuts 5% of Commercial Airplane Jobs, Delays 737 Monthly Production Target of 47 Aircraft to 2027
Stephanie Pope, head of Boeing's commercial airplanes division, informed employees in an internal memo on Monday that due to obstacles in increasing aircraft production, the division plans to cut 5% of its workforce.
Crypto prices
More
